GlycoMimetics' Uproleselan Shows Promise in Acute Myeloid Leukemia Trials
Key Insights
GlycoMimetics (search) will present Phase 3 trial data on uproleselan plus chemotherapy in relapsed/refractory AML (search) at the ASH Annual Meeting.
Updated Phase 1 results of uproleselan with azacitidine and venetoclax in treatment-naive AML (search) will also be presented.
Final Phase 2 data of uproleselan combined with cladribine and low-dose cytarabine for treated secondary AML (search) will be shared.
GlycoMimetics (search), Inc. (Nasdaq: GLYC) is set to present new clinical data on uproleselan, a glycobiology-based therapy, across multiple trials for acute myeloid leukemia (search) (AML (search)) at the 66th American Society of Hematology (ASH) Annual Meeting, held December 7-10, 2024, in San Diego, California. The presentations will cover uproleselan's efficacy and safety in various AML patient populations, including relapsed/refractory, treatment-naive, and treated secondary AML.
Phase 3 Trial in Relapsed/Refractory AML
An oral presentation (Publication Number 733) by Daniel DeAngelo, M.D., Ph.D., will highlight findings from an international Phase 3 trial evaluating uproleselan combined with chemotherapy versus chemotherapy alone in patients with relapsed or refractory AML (search). This session, titled "Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia (search): Findings from an International Phase 3 Trial," is scheduled for Monday, December 9, 2024, from 10:30 AM to 12:00 PM PT.
Phase 1 Study in Treatment-Naive AML
Brian Jonas, M.D., Ph.D., will present updated results from a Phase 1 study (Publication Number 1503) assessing uproleselan in combination with azacitidine and venetoclax for older or unfit patients with treatment-naive AML (search). The poster presentation, titled "Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naive Acute Myeloid Leukemia (search)," is scheduled for Saturday, December 7, 2024, from 5:30 PM to 7:30 PM PT.
Phase 2 Study in Treated Secondary AML
Caitlin Rausch, PharmD, will present final results from a Phase 2 study (Publication Number 4262) of uproleselan combined with cladribine and low-dose cytarabine for patients with treated secondary AML (search) (ts-AML). The poster, titled "Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (search) (ts-AML)," will be presented on Monday, December 9, 2024, from 6:00 PM to 8:00 PM PT.
GlycoMimetics (search) is focused on developing glycobiology-based therapies for cancers and inflammatory diseases. Their approach centers on understanding the role of carbohydrates in cell recognition and utilizing glycomimetics to modulate these interactions in disease states.